Entries by raincastle

Novel markers to predict virological and clinical relapse onset following antiviral treatment discontinuation in chronic hepatitis B patients

March 5, 2021 — Applying algorithms to interconnected biomarker and clinical data can yield scientific insights, not only into therapeutic mechanisms, but also into predicting long-term response to treatment. In a collaboration with investigators at Janssen, the QuartzBio team sought to identify genetic markers correlated with protection against chronic hepatitis B early relapse in patients […]

Join QuartzBio at the SCOPE 2021 Virtual Conference for Clinical Operations Executives

Join QuartzBio at the SCOPE 2021 virtual conference for the “Clinical Biomarkers Operations and Innovation” track on March 2. PRESENTATION: “Centralizing PK, Clinical, and Exploratory Biospecimen Data to Streamline Trial Operations & Intelligence” Clinical samples are frequently a logistical headache – managed too often in Excel files that are time-consuming to update, and quickly fall […]

Webinar On Demand: Critical On-Study Biomarker KPIs for Modern Trials – Part 2

Register here for the webinar Title: Critical On-Study Biomarker KPIs for Modern Trials – Part 2: Integrating Data Silos to Unlock Scientific Insights and Empower Translational Teams Duration: 45 minutes You will learn how to: Expand your use of exploratory biomarker data in combination with clinical metadata for on-study analytics Centralize integrated biomarker and clinical data […]

Translational Intelligence: Unlocking Insights from Expansive Biomarker Data

February 3, 2021 — In this brief, we explore Translational Intelligence – that is, navigating the vast biomarker data ecosystem to quickly uncover insights that would be missed by visual inspection alone, and which enable translational teams to focus on the right pathways, biological mechanisms, and / or patient populations.

Generating Value from Public, Large Scale Biomedical Datasets — Video

February 1, 2021 — Translational and clinical researchers everywhere are harnessing public multiomics data sets to accelerate R&D. Renée Deehan, Ph.D., VP of Computational Biology at QuartzBio, described the enormous potential of public, real-world data at a panel discussion hosted by OBN.

Integrating Data and Knowledge from The Cancer Genome Atlas to Accelerate R&D

January 27, 2021 — Non-profit and governmental organizations have invested immense financial and labor resources, with generous contributions from participants, to create large-scale data sets. The Cancer Genome Atlas (TCGA) is one such publicly accessible resource, and represents a uniquely comprehensive collection of multiomic and clinical data, from which drug development researchers can derive knowledge […]

Reverse causal inferencing on molecular data from lung adenocarcinoma patients reveals a stem cell–like molecular subtype associated with pack-year history

November 9, 2020 — Advances in high throughput measurement technologies (omics data) have made it possible, and increasingly affordable, to generate high complexity, high volume data for oncology research. QuartzBio’s Renee Deehan poster, “Reverse Causal Inferencing on Lung Adenocarcinoma Patients Reveals a Stem Cell–Like Molecular Subtype Associated with Pack-Year History,” is an insightful look into […]